How many drugs treat Migraine Prevention?

Drug Landscape tracks 7 marketed treatments for Migraine Prevention (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Migraine Prevention?

Most recent: Topamax — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/migraine-prevention.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Migraine Prevention — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Migraine Prevention (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Migraine Prevention, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Depakene	valproic acid	Generic (originally Abbott/AbbVie)	Anti-epileptic Agent [EPC]	Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2	1978-02-28
Inderal	propranolol	Generic (originally ICI/AstraZeneca)	Non-selective beta-blocker	Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2	1967-11-13
Epilim	sodium valproate	Sanofi		Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2
Topamax	topiramate	Janssen		Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12
PF-07976016 Formulation A	pf-07976016-formulation-a	Pfizer	Unknown	Unknown
Topamax	Topamax	Ataturk University		Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12
Divalproex	Divalproex	University of Chicago		Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-18 — Topamax · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Migraine Prevention
Ataturk University · 1 drug in Migraine Prevention
Generic (originally Abbott/AbbVie) · 1 drug in Migraine Prevention
Generic (originally ICI/AstraZeneca) · 1 drug in Migraine Prevention
Janssen · 1 drug in Migraine Prevention
Pfizer · 1 drug in Migraine Prevention
Sanofi · 1 drug in Migraine Prevention
University of Chicago · 1 drug in Migraine Prevention

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Migraine Prevention:

Cite this brief

Drug Landscape (2026). Migraine Prevention — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/migraine-prevention. Accessed 2026-06-10.

Migraine Prevention full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing